In bladder cancer, however, few studies have investigated the impact of circulating HGF (Gohji et al. 2000; Wang et al. 2007), and due to limitations of their sample size and study design, the significance and clinical utility of blood levels of HGF for the prediction of worse pathologic or poor survival outcomes remains unclear. The gene discussed is HGF; the disease is urinary bladder cancer.